Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 1

| *Complete if Known* | |
|---|---|
| Application Number | 10/584,072 |
| Filing Date | June 22, 2006 |
| First Named Inventor | Siegfried Ansorge et al. |
| Group Art Unit | 1614 |
| Examiner Name | Chris E. Simmons |
| Attorney Docket Number | PMP-0003 |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T [2] |
|---|---|---|---|
| | C1 | TERAMOTO, Shinji et al., "Effects of Antiotensin-Converting Enzyme Inhibitors on Spontaneous or Stimulated Generation of Reactive Oxygen Species by Bronchoalveolar Lavage Cells Harvested From Patients With or Without Chronic Obstructive Pulmonary Disease," Jpn. J. Pharmacol., vol. 83, 2000, pgs. 56-62. | |
| | C2 | BERKSEN, Burton M., "A Conservative Triple Antioxidant Approach to the Treatment of Hepatitis C," Medizinische Klinik, vol. 94, 1999, Suppl. III, pgs. 84-89. | |
| | C3 | BUHL, Roland et al., "Antioxidanzien zur Therapie von Lungenerkrankungen," MMP, vol. 18 no. 10, 1998, pgs. 287-293. NOT IN ENGLISH | |
| | C4 | BIEWENGA, G. et al., "Lipoic acid favors thiosulfinate formation after hypochlorous acid scavenging: a study with lipoic acid derivatives," Arch Biochem Biophys., July 1994, vol. 312 no. 1, pgs. 114-120. ABSTRACT ONLY | |
| | C5 | MALERBA, Mario et al., "Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST trial)," Pulmonary Pharmacology and Therapeutics, vol. 17, 2004, pgs. 27-34. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Examiner Signature | /Chris Simmons/ | Date Considered | 05/22/2008 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./